Compare DUOT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | MXCT |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 160.0M |
| IPO Year | N/A | 2021 |
| Metric | DUOT | MXCT |
|---|---|---|
| Price | $10.99 | $1.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $14.00 | $7.50 |
| AVG Volume (30 Days) | 193.6K | ★ 1.3M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,026,308.00 | ★ $34,419,000.00 |
| Revenue This Year | $292.26 | N/A |
| Revenue Next Year | $43.21 | $10.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 159.00 | N/A |
| 52 Week Low | $3.84 | $1.26 |
| 52 Week High | $12.17 | $5.20 |
| Indicator | DUOT | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 48.38 |
| Support Level | $9.25 | $1.48 |
| Resistance Level | $12.17 | $1.60 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 61.04 | 45.95 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.